Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire achieves clinical success with four novel products
Data from both phase II and phase III clinical trials evaluated the following four compounds: MTS, SPD503 and NRP104, all for the treatment of ADHD, and SPD476 for
Data from both phase II and phase III clinical trials evaluated the following four compounds: MTS, SPD503 and NRP104, all for the treatment of ADHD, and SPD476 for
Reata has initiated a preclinical development program with peloruside A, the first identified compound in the class, which could enter clinical testing as early as 2007. Peloruside A
Entocort EC (budesonide) is a topical glucocorticosteriod, working primarily in the intestines. It is the only pharmacological product indicated for the treatment of mild to moderate Crohn’s disease
Gross profit from continuing operations was $2.8 million or 56% during the first quarter of 2009 compared to $3.6 million or 58% during the comparable period of 2008.
The company has already begun efficacy and safety studies of its RNA interference (RNAi)-based therapeutic treatment in anaimals models to facilitate its FDA application. Benitec believes it is
Under the agreement, Dowpharma’s proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen’s prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein
The drug was well tolerated and demonstrated potent antiviral activity in a phase I clinical trial involving 34 patients with chronic genotype 1 hepatitis C virus infection. The
The fill/finish plant bought from BioReliance Corporation, a subsidiary of Invitrogen Corporation, will be used to develop and expand Acambis’ vaccine range covering smallpox, West Nile disease and
Ergothioneine concentrates in tissues and organs that undergo the most oxidative stress in humans, yet ergothioneine must be ingested in humans because the body does not produce it.
The patent infringement suit surrounding Sanofi-Aventis’s Plavix, the world’s third largest selling medication, was previously scheduled for May 13, 2005. Canadian company Apotex and India’s Dr Reddy’s Laboratories,